New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
09:18 EDTPCYCPharmacyclics price target raised to $166 from $154 at Roth Capital
Roth Capital increased its price target on Pharmacyclics after the FDA approved the company's IMBRUVICA for chronic lymphocytic leukemia. The firm expects sales of the drug to be strong and keeps a Buy rating on the shares.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent PCYC news | >>
February 26, 2015
09:03 EDTPCYCPharmacyclics price target raised to $240 from $200 at RW Baird
Subscribe for More Information
06:52 EDTPCYCPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTPCYCPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTPCYCPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
14:02 EDTPCYCPharmacyclics downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
13:30 EDTPCYCPharmacyclics calls active on exploring options reports
Pharmacyclics March 220 and April 230 calls are active on total call volume of 4,200 contracts (3,100 puts) on exploring options including sale, Bloomberg reports. Active call volume suggests traders taking positions for upside price movement.
12:54 EDTPCYCPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTPCYCPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
12:50 EDTPCYCPharmacyclics jumps 19% after Bloomberg says weighing sale
Subscribe for More Information
February 19, 2015
09:59 EDTPCYCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:59 EDTPCYCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
07:41 EDTPCYCPharmacyclics price target raised to $204 from $153 at Leerink
Subscribe for More Information
06:32 EDTPCYCPharmacyclics price target raised to $205 from $180 at Deutsche Bank
Subscribe for More Information
06:24 EDTPCYCPharmacyclics downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:15 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:08 EDTPCYCPharmacyclics upgraded to Buy from Neutral at Nomura
Subscribe for More Information
February 18, 2015
16:06 EDTPCYCPharmacyclics reaffirms 2015 product revenue guidance
Subscribe for More Information
16:04 EDTPCYCPharmacyclics reports Q4 EPS 96c, consensus 76c
Subscribe for More Information
15:35 EDTPCYCNotable companies reporting after market close
Subscribe for More Information
February 17, 2015
09:05 EDTPCYCPharmacyclics announces positive results from treatment with IMBRUVICA
Pharmacyclics announced that treatment with IMBRUVICA was associated with an 88% overall response rate, or ORR, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory, or R/R, high-risk chronic lymphocytic leukemia. These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival, or PFS, at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplant, a procedure in which stem cells from one person are transplanted to another. A second presentation during the BMT Tandem meeting highlighted data from five patients with R/R CLL who had undergone allo-HCT. The researchers concluded that these results support further study of IMBRUVICA in patients following allo-HCT, including those patients with chronic GVHD. Study PCYC 1129, a multicenter open--label Phase Ib/II study of IMBRUVICA in steroid--dependent or refractory chronic GVHD patients, has completed its Phase Ib without dose limiting toxicities and is now enrolling the Phase II portion at the recommended Phase II dose of 420 mg.
1 | 2 | all recent PCYC news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use